Medistim ASA (OSL:MEDI)
Norway · Delayed Price · Currency is NOK 300.00
+19.00 (6.76%)
Oct 23, 2026, 4:25 PM CEST
Medistim ASA Income Statement
Financials in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 795.98 | 699.77 | 562.6 | 521.11 | 486.26 | 417.82 | |
Revenue Growth | 19.05% | 24.38% | 7.96% | 7.17% | 16.38% | 17.30% |
Cost of Revenue | 145.8 | 128.17 | 113.68 | 112.28 | 106.49 | 97.11 |
Gross Profit | 650.18 | 571.59 | 448.92 | 408.83 | 379.78 | 320.7 |
Selling, General & Admin | 247.08 | 216.66 | 174.35 | 150.2 | 136.51 | 124.02 |
Other Operating Expenses | 148.52 | 133.91 | 118.98 | 103.53 | 78.73 | 62.27 |
Operating Expenses | 422.34 | 375.4 | 317.84 | 277.39 | 238.53 | 209.72 |
Operating Income | 227.84 | 196.2 | 131.08 | 131.44 | 141.25 | 110.99 |
Interest Expense | -29.78 | -0.54 | -0.32 | - | -0.12 | -0.18 |
Interest & Investment Income | 1.84 | 5 | 4.57 | 3.28 | 0.92 | 0.02 |
Currency Exchange Gain (Loss) | 6.54 | 10.41 | -1.63 | 0.93 | 3.06 | -1.81 |
Other Non Operating Income (Expenses) | 23.65 | -4.21 | 0.56 | -0.44 | 0.94 | -0.24 |
EBT Excluding Unusual Items | 230.09 | 206.85 | 134.25 | 135.21 | 146.05 | 108.78 |
Other Unusual Items | - | - | - | - | - | 5.29 |
Pretax Income | 230.09 | 206.85 | 134.25 | 135.21 | 146.05 | 114.07 |
Income Tax Expense | 51.7 | 47.64 | 30.41 | 31.39 | 32.08 | 23.17 |
Net Income | 178.39 | 159.21 | 103.83 | 103.82 | 113.97 | 90.9 |
Net Income to Common | 178.39 | 159.21 | 103.83 | 103.82 | 113.97 | 90.9 |
Net Income Growth | 25.25% | 53.33% | 0.01% | -8.91% | 25.38% | 31.00% |
Shares Outstanding (Basic) | - | 18 | 18 | 18 | 18 | 18 |
Shares Outstanding (Diluted) | - | 18 | 18 | 18 | 18 | 18 |
Shares Change | - | -0.21% | 0.10% | 0.10% | 0.15% | 0.07% |
EPS (Basic) | - | 8.71 | 5.67 | 5.68 | 6.25 | 4.99 |
EPS (Diluted) | - | 8.71 | 5.67 | 5.67 | 6.24 | 4.98 |
EPS Growth | - | 53.63% | -0.01% | -9.13% | 25.30% | 31.05% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 202.55 | 181.59 | 137.04 | 102.8 | 104.24 | 119.97 |
Free Cash Flow Per Share | - | 9.94 | 7.48 | 5.62 | 5.70 | 6.57 |
Dividend Per Share | 8.000 | 8.000 | 6.000 | 4.500 | 4.500 | 3.750 |
Dividend Growth | 33.33% | 33.33% | 33.33% | 0% | 20.00% | 25.00% |
Gross Margin | 81.68% | 81.68% | 79.79% | 78.45% | 78.10% | 76.76% |
Operating Margin | 28.62% | 28.04% | 23.30% | 25.22% | 29.05% | 26.56% |
Profit Margin | 22.41% | 22.75% | 18.46% | 19.92% | 23.44% | 21.76% |
Free Cash Flow Margin | 25.45% | 25.95% | 24.36% | 19.73% | 21.44% | 28.71% |
EBITDA | 250.17 | 212.21 | 146.47 | 146.72 | 157.45 | 127.26 |
EBITDA Margin | 31.43% | 30.33% | 26.04% | 28.16% | 32.38% | 30.46% |
D&A For EBITDA | 22.33 | 16.02 | 15.4 | 15.27 | 16.2 | 16.27 |
EBIT | 227.84 | 196.2 | 131.08 | 131.44 | 141.25 | 110.99 |
EBIT Margin | 28.62% | 28.04% | 23.30% | 25.22% | 29.05% | 26.56% |
Effective Tax Rate | 22.47% | 23.03% | 22.66% | 23.21% | 21.96% | 20.31% |
Revenue as Reported | - | - | - | 526.36 | 491.94 | 427.28 |